ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD 1 JANUARY - 30 SEPTEMBER 2014

(ORIGINALLY ISSUED IN TURKISH)

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE INTERIM PERIOD 1 JANUARY - 30 SEPTEMBER 2014

CONTENTS	P	AGE(S)
CONDENSE	D CONSOLIDATED BALANCE SHEET	1-2
	D CONSOLIDATED STATEMENT OF INCOME AND STATEMENT OF COMPREHENSIVE	3-4
CONDENSEI	D CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY	5
CONDENSEI	D CONSOLIDATED STATEMENT OF CASH FLOW	6-7
NOTES TO 1	THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	8-38
NOTE 1	ORGANIZATION AND OPERATIONS OF THE GROUP	8-9
NOTE 2	BASIS OF PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9-12
NOTE 3	BUSINESS COMBINATIONS	12
NOTE 4	SEGMENTAL INFORMATION	13
NOTE 5	CASH AND CASH EQUIVALENTS	13
NOTE 6	FINANCIAL INVESTMENTS	13-14
NOTE 7	FINANCIAL LIABILITIES	14-15
NOTE 8	TRADE RECEIVABLES AND PAYABLES	16
NOTE 9	OTHER RECEIVABLES AND PAYABLES	16-17
NOTE 10	INVENTORIES	17
NOTE 11	INVESTMENT PROPERTIES	18
NOTE 12	TANGIBLE ASSETS	19-21
NOTE 13	INTANGIBLE ASSETS	21-22
NOTE 14	CONTINGENT ASSETS AND LIABILITIES	23
NOTE 15	REVENUE AND COST OF SALES	23
NOTE 16	EXPENSES BY NATURE	24
NOTE 17	FINANCIAL INCOME	24
NOTE 18	FINANCIAL EXPENSES.	24
NOTE 19	TAX ASSET AND LIABILITIES (INCLUDING DEFERRED TAX ASSET AND LIABILITIES).	25-27
NOTE 20	EARNINGS PER SHARE	27
NOTE 21	BALANCES AND TRANSACTIONS WITH RELATED PARTIES	27-31
NOTE 22	NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS	32-34
NOTE 23	FINANCIAL INSTRUMENTS	34-36
NOTE 24	EVENTS AFTER THE BALANCE SHEET DATE	36
NOTE 25	SALES OF SUBSIDIARIES	36-38

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS AS OF 30 SEPTEMBER 2014 AND 31 DECEMBER 2013

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

ASSETS	Notes	Unaudited Current Period 30 September 2014	Audited Previous Period 31 December 2013
Current Assets		1.412.562.280	2.128.504.531
Cash and Cash Equivalent	5	342.540.789	1.164.383.158
Financial Investments	6	770.107	611.476
Trade Receivables			
- Due From Related Parties	8-21	605.683.405	446.815.319
- Other Trade Receivables	8	39.214.246	201.954.749
Other Receivables			
- Due From Related Parties	9-21	223.586	3.417.357
- Other Receivables	9	366.439	16.860.567
Inventories	10	255.737.568	198.321.733
Prepaid Expenses		111.567.535	47.436.206
Current Income Tax Assets		1.818.827	1.879.695
Other Current Assets		54.639.778	46.824.271
Non-Current Assets		1.050.576.514	1.033.447.409
Financial Investments Other Receivables	6	467.345.369	464.661.239
- Other Receivables	9	175.288	161.464
Investment Properties	11	10.035.000	10.035.000
Tangible Assets	12	546.449.700	532.558.107
Intangible Assets	13	1.231.399	791.589
Prepaid Expenses		16.411.920	20.991.312
Deferred Tax Assets	19	8.923.652	4.244.512
Other Non-Current Assets		4.186	4.186
TOTAL ASSETS		2.463.138.794	3.161.951.940

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS AS OF 30 SEPTEMBER 2014 AND 31 DECEMBER 2013

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

LIABILITIES AND SHAREHOLDERS' EQUITY		Unaudited Current Period 30 September	Audited Previous Period 31 December
-	Notes	2014	2013
Current Liabilities		1.304.655.455	1.826.580.192
Short Term Financial Liabilities	7	100.698.813	150.942.003
Short-Term Portion of Long-Term Financial Liabilities	7	733.841.163	1.098.791.211
Trade Payables			
- Due to Related Parties	8-21	212.162.684	273.321.957
- Other Trade Payables	8	200.882.728	235.142.437
Employee Benefit Related Liabilities		18.261.782	17.716.822
Other Payables			
- Due to Related Parties	9-21	-	86.857
- Other Payables	9	1.381.014	344.940
Current Income Tax Liabilities	19	12.903.225	11.471.653
Short Term Provisions			
- Provisions for Employee Benefits		10.654.996	14.273.061
- Other Short Term Provisions		6.501.238	8.699.625
Other Current Liabilities		7.367.812	15.789.626
Non-Current Liabilities		54.524.196	67.203.301
Long Term Financial Liabilities	7	-	9.851.176
Long Term Provisions			
- Provisions for Employee Benefits		25.909.016	23.380.797
Deferred Tax Liabilities Other Non-Current Liabilities		28.403.249 211.931	33.935.757 35.571
Other Non-Current Liabilities		211.931	33.371
SHAREHOLDERS' EQUITY		1.103.959.143	1.268.168.447
Equity Attributable To Equity Holders' of the Parent		1.019.411.501	1.129.829.508
Share Capital		342.000.000	342.000.000
Inflation Adjustments to Share Capital		108.056.201	108.056.201
Other Comprehensive Income/Expense not to be			
Reclassified to Profit and Loss - Actuarial Losses		(417 621)	(1 207 950)
- Actuariar Losses - Investment Property Valuation Funds		(417.621)	(1.307.850) 5.231.735
Other Comprehensive Income/Expense to be		5.231.735	3.231.733
Reclassified to Profit and Loss			
- Financial Assets Valuation Fund		257.045.237	254.670.905
Restricted Reserves Appropriated from Profits		150.366.889	126.205.350
Retained Earnings		1.880.973	106.324.722
Net Profit for the Period		155.248.087	188.648.445
Non-Controlling Interest		84.547.642	138.338.939
TOTAL LIABILITIES AND EQUITY		2.463.138.794	3.161.951.940

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME FOR THE INTERIM PERIODS ENDED 30 SEPTEMBER 2014 AND 2013

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

				Reclassified (*)	Reclassified (*)
		Unaudited	Unaudited	Unaudited	Unaudited
		Current Period	Current Period	Previous	Previous
		1 January-	1 July-	Period 1 January-	Period 1 July-
		30 September	30 September	30 September	30 September
	Notes	2014	2014	2013	2013
_					
Revenue	15	2.123.185.388	672.655.081	1.978.409.277	652.129.790
Cost of Sales (-)	15	(1.681.834.092)	(547.203.570)	(1.523.609.344)	(507.508.014)
GROSS PROFIT FROM OPERATIONS		441.351.296	125.451.511	454.799.933	144.621.776
Research Expenses (-)	16	(10.168.059)	(2.473.480)	(9.736.638)	(1.946.982)
Marketing Expenses (-)	16	(169.652.853)	(46.124.138)	(177.434.936)	(57.134.679)
General Administrative Expenses (-)	16	(67.281.368)	(18.287.789)	(73.151.665)	(23.446.104)
Other Income from Main Operations		122.787.234	17.371.545	111.237.764	35.544.211
Other Expenses from Main Operations (-)		(112.862.622)	(12.282.751)	(119.074.020)	(41.128.197)
OPERATING PROFIT FROM MAIN OPERATION		204.173.628	63.654.898	186.640.438	56.510.025
Income from Investment Activities		197.105.949	18.062.976	174.215.864	68.382.013
Expenses from Investment Activities (-)		(118.584.041)	(83.552)	(21.568.649)	(7.159.257)
OPERATING PROFIT BEFORE FINANCIAL INCOME AND EXPENSES		282.695.536	81.634.322	339.287.653	117.732.781
Financial Income	17	59.481.556	15.361.064	23.863.530	8.420.816
Financial Expenses (-)	18	(154.751.951)	(54.033.347)	(172.203.594)	(73.610.119)
PROFIT BEFORE TAX		187.425.141	42.962.039	190.947.589	52.543.478
Tax Expense	19	(19.500.915)	(5.193.936)	(38.946.622)	(11.526.797)
Tax on Income (-)		(32.463.604)	(10.274.412)	(44.321.886)	(14.034.306)
Deferred Tax Income / (Expense)		12.962.689	5.080.476	5.375.264	2.507.509
PROFIT FOR THE PERIOD		167.924.226	37.768.103	152.000.967	41.016.681
Distribution of the Profit for the Period					
Non-Controlling Interest		12.676.139	2.126.075	29.432.142	10.210.022
Equity Holders of the Parent		155.248.087	35.642.028	122.568.825	30.806.659
Earnings Per Share	20	0,45	0,10	0,36	0,09

^(*) Reclassification effects have been explained in Note 2.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE INTERIM PERIODS ENDED 30 SEPTEMBER 2014 AND 2013 (Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

	Unaudited Current Period 1 January- 30 September 2014	Unaudited Current Period 1 July- 30 September 2014	Unaudited Previous Period 1 January- 30 September 2013	Unaudited Previous Period 1 July- 30 September 2013
PROFIT FOR THE PERIOD	167.924.226	37.768.103	152.000.967	41.016.681
Other Comprehensive Income/(Loss):				
Items not to be Reclassified Under Profit and Loss	1.202.568	991.160	(15.630.237)	(15.314.318)
Change In Revaluation Funds Of Investment Properties Actuarial Gain/(Loss)	1.503.210	1.238.950	(15.417.141) (280.826)	(15.417.141) 89.073
Tax Income/(Expenses) Related to Other Comprehensive Income not to be Reclassified Under Profit and Loss (Note 19)	(300.642)	(247.790)	67.730	13.750
Items to be Reclassified Under Profit and Loss	2.590.086	(512.324)	(1.201.474)	(92.549)
Change in Revaluation Funds of Financial Assets	2.726.406	(539.289)	(1.264.710)	(96.952)
Tax (Expense)/Income Related to Other Comprehensive Income to be Reclassified Under Profit and Loss (Note 19)	(136.320)	26.965	63.236	4.403
OTHER COMPREHENSIVE INCOME/(LOSS)	3.792.654	478.836	(16.831.711)	(15.406.867)
TOTAL COMPREHENSIVE INCOME	171.716.880	38.246.939	135.169.256	25.609.814
Distribution of Total Comprehensive Income	12.201.533	2.120.52=	20.224.455	40.004.607
Non-Controlling Interest Equity holders of the Parent	13.204.232 158.512.648	2.138.537 36.108.402	29.334.473 105.834.783	10.201.091 15.408.723
Equity holders of the further	130.312.070	30.100.402	103.034.703	13.700.723

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE INTERIM PERIODS ENDED 30 SEPTEMBER 2014 AND 2013 (Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

			Accumulated Other								
			Comprehensive								
			Income To Be	Accumula	ated Other						
			Reclassified		Income Not To						
			Under Profit And Loss		d Under Profit Loss		Accum Pro		Equity		
		Inflation	Financial	Investment	Loss	Restricted	110	iiit	Attributable to		
		Adjustments	Assets	Property		Reserves	Net Profit		Equity	Non-	
	Share	to Share	Valuation Fund	Valuation Fund	Actuarial Loss	Appropriated from Profits	for the Period	Retained	Holders of the	Controlling	Total
Balances as of 1 January 2013	Capital 342.000.000	Capital 108.056.201	123.114.916	20.637.311	(1.912.682)	73.181.956	166,968,003	Earnings 125.405.583	Parent 957.451.288	Interest 122.302.124	Equity 1.079.753.412
Total comprehensive income	-	-	(1.101.392)	(15.405.575)	(227.075)	-	122.568.825	-	105.834.783	29.334.473	135.169.256
Dividend paid	-	-	-	-	-	_	-	(150.000.000)	(150.000.000)	(22.670.315)	(172.670.315)
Sale of Investment Property	_	-	-	-	-	-	-	15.405.575	15.405.575	-	15.405.575
Transactions under common control (*)	-	-	-	-	-	-	-	1.514.926	1.514.926	-	1.514.926
Transfers	-	-	-	-	-	53.023.394	(166.968.003)	113.944.609	-	-	-
Balances as of 30 September 2013	342.000.000	108.056.201	122.013.524	5.231.736	(2.139.757)	126.205.350	122.568.825	106.270.693	930.206.572	128.966.282	1.059.172.854
Balances as of 1 January 2014	342.000.000	108.056.201	254.670.905	5.231.735	(1.307.850)	126.205.350	188.648.445	106.324.722	1.129.829.508	138.338.939	1.268.168.447
Total comprehensive income	-	-	2.374.332	-	890.229	-	155.248.087	-	158.512.648	13.204.232	171.716.880
Dividend paid	-	-	-	-	-	-	-	(133.000.000)	(133.000.000)	(6.249.993)	(139.249.993)
Transactions under common control (**)	-	-	-	-	-	-	-	4.153.364	4.153.364	(829.555)	3.323.809
Transactions with Non-controlling interests (***)	-	-	-	-	-	-	-	(140.084.019)	(140.084.019)	(59.915.981)	(200.000.000)
Transfers	-	_	-	-	-	24.161.539	(188.648.445)	164.486.906	-	-	
Balances as of 30 September 2014	342.000.000	108.056.201	257.045.237	5.231.735	(417.621)	150.366.889	155.248.087	1.880.973	1.019.411.501	84.547.642	1.103.959.143

^(*) Reform Gida Paz. San. ve Tic. A.Ş. acquisition (Note 3).

^(**) Consist of İstanbul Gıda Dış Ticaret A.Ş., Birleşik Dış Ticaret A.Ş., and Rekor Gıda Pazarlama A.Ş.'s disposal (Note 25).

^(***) Ülker Bisküvi San. A.Ş's acquisition of Biskot Bisküvi Gıda San. ve Tic. A.Ş.'s share by 30% (Note 1).

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

	Notes	Unaudited Current Period 1 January- 30 September 2014	Unaudited Previous Period 1 January- 30 September 2013
CASH FLOWS FROM OPERATING ACTIVITIES		4.7.004.004	4.50.00.045
Net profit for the period		167.924.226	152.000.967
Adjustments to reconcile net profit / (loss) to net cash provided by operating ac		40.050.756	29 274 205
- Depreciation expenses of tangible assets	12	40.850.756	38.274.295
- Amortization expenses of intangible assets	13	293.649	182.937
 Loss on Sale of Investment Properties 	8	-	3.526.906
- Allowance for doubtful receivables	8	475.245	121.115
- Provision for employment benefits		12.717.233	6.775.909
- Provision for unused vacation		1.663.059	2.814.582
- Performance premium provision		641.776	4.412.142
- Provision for lawsuits		260.078	(54.269)
- Provision for sales return		(2.568.884)	(1.959.448)
- Change in loan expense accrual		3.909.102	(7.187.770)
- Discount expense		1.000.360	2.704.414
Change in foreign currency and interest expense of financial liabilities (net)		68.485.775	147.353.909
- Gain on sale of derivative financial instruments		-	(409.549)
- Gain on sale of tangible and intangible assets (net)		1.189.531	(2.331.330)
- Reversal of provision for inventory allowance	10	(1.135.677)	(4.148.587)
- Rent income		(5.830.352)	(5.758.189)
- Dividend income		(671.159)	(434.428)
- Change in foreign currency from investment activities (net)		(51.058.652)	(117.618.577)
- Interest income		(22.151.276)	(30.029.510)
- Tax provision	19	19.500.915	38.946.622
Net Operating cash flows provided before changes in working capital		235.495.705	227.182.141
- Increase in trade receivables		23.887.038	9.738.996
- Increase in trade receivables from related parties		(80.413.841)	(88.147.508)
- (Increase)/decrease in inventories		(60.893.225)	(10.154.069)
- (Decrease)/increase in other receivables and other current assets		(55.499.896)	(49.175.847)
- Decrease in trade payables		(21.555.340)	(48.472.911)
- Increase/(decrease) in trade payables to related parties		(38.428.280)	(10.367.581)
- Decrease in other payables and liabilities		9.392.891	21.134.818
Net cash generated from operations		11.985.052	51.738.039
- Taxes paid	19	(31.032.032)	(31.316.446)
- Employment termination benefit paid	1,	(8.000.705)	(4.888.465)
- Unused vacation paid		(2.745.094)	(2.046.216)
- Performance premium paid		(3.177.806)	(4.963.236)
- Lawsuits provision paid		(314.347)	(343.801)
- Collections from doubtful trade receivables	8	4.971	108.647
Net cash generated from operating activities	Ü	(33.279.961)	8.288.522
		(22.2170701)	J.200.22

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

		Unaudited	Unaudited
	Notes	Current Period 1 January- 30 September 2014	Previous Period 1 January- 30 September 2013
CASH FLOWS FROM INVESTING ACTIVITIES			
- Acquisition of tangible assets	12	(58.432.536)	(49.037.969)
- Acquisition of intangible assets	13	(418.686)	(45.752)
- Proceeds from sales of investment properties		-	17.118.094
- Proceeds from sales of tangible and intangible assets		1.579.953	20.981.627
- Proceeds from sales of Subsidiaries		35.751.007	-
- Acquisition of shares of subsidiaries		(200.000.000)	-
- Change in non-trade receivables from related parties		71.979.204	243.154.171
- Rent income		5.830.352	5.758.189
- Dividend income		671.159	434.428
- Interest received		22.151.276	30.029.510
- Change in financial assets		(158.631)	(534.026)
Net cash generated from investing activities		(121.046.902)	267.858.272
CASH FLOWS FROM FINANCING ACTIVITIES			
- Loan repayment		(272.433.696)	(475.811.131)
- Loans acquired		114.855.922	122.477.544
- Change in leasing liabilities		(5.078.735)	(5.480.655)
- Dividend paid		(139.249.993)	(172.670.315)
- Interest paid		(18.528.719)	(39.427.020)
- Changes in non-trade payables to related parties		(10.202.533)	209.633
Net cash used in financing activities		(330.637.754)	(570.701.944)
NET CHANGE IN CASH AND CASH EQUIVALENTS		(484.964.617)	(294.555.150)
	5	1.164.383.158	1.267.728.071
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIO	D		
Cash outflow due to subsidiary disposal		(336.877.752)	-
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	5	342.540.789	973.172.921

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

1. ORGANIZATION AND OPERATIONS OF THE GROUP

Ülker Bisküvi Sanayi A.Ş. ("the Company") and its subsidiaries (all together "the Group"), comprises of the parent Ülker Bisküvi Sanayi A.Ş. ("the Company") and four subsidiaries in which the Company owns the majority share of the capital or which are controlled by the Company (2013: seven).

Ülker Bisküvi Sanayi A.Ş. was established in 1944. The Company's core business activities are manufacturing of biscuits, chocolate, chocolate coated biscuits, wafers and cakes.

Ülker Bisküvi Sanayi A.Ş. which is registered at the Capital Market Board, merged under its own title with Anadolu Gıda Sanayi A.Ş., whose shares have been quoted on Borsa Istanbul since 30 October 1996, as of 31 December 2003.

The headquarter of Ülker Bisküvi Sanayi A.Ş. is located Kısıklı Mah. Ferah Cad. No:1 Büyük Çamlıca Üsküdar / Istanbul.

As of 30 September 2014, the total number of people employed by the Group is 8.551, which contains 567 employees who worked as subcontractors (2013: 9.218, subcontractor: 519).

The ultimate parent and the controlling party of the Group is Yıldız Holding A.Ş. The ultimate parent of Yıldız Holding A.Ş. is managed by Ülker Family.

As of 30 September 2014 and 31 December 2013, the names and percentages of the shareholders holding more than 10% of the Company's share capital are as follows:

		30 September 2014		31 December 2013
Name of the Shareholders	Share	Percentage	Share	Percentage
Yıldız Holding A.Ş.	167.122.180	48,87%	166.967.458	48,82%
Yıldız Holding A.Ş. Subsidiaries and Ülker Family	27.736.320	8,11%	38.888.808	11,37%
Other	147.141.500	43,02%	136.143.734	39,81%
	342.000.000	100,00%	342.000.000	100,00%

As of 30 September 2014 and 31 December 2013, the details of the subsidiaries in terms of direct and effective share of ownership and principal business activities are as follows:

	30 September 2014		31 Decem	ber 2013	
	Ratio of Direct	Ratio of Effective	Ratio of Direct	Ratio of Effective	
	Ownership	Ownership	Ownership	Ownership	Nature of
Subsidiaries	%	%	%	%	Operations
Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş. (*)	73,9%	73,9%	43,5%	43,9%	Manufacturing
Ülker Çikolata Sanayi A.Ş.	91,7%	91,7%	91,7%	91,7%	Manufacturing
Atlas Gıda Pazarlama Sanayi ve Ticaret A.Ş.	98,3%	98,3%	98,3%	98,3%	Trading
Reform Gıda Paz. San. ve Tic. A.Ş.	100,0%	100,0%	100,0%	100,0%	Trading
İstanbul Gıda Dış Ticaret A.Ş.(**)	-	-	83,8%	91,4%	Sales&Marketing
Birleşik Dış Ticaret A.Ş. (***)	-	-	70,0%	79,2%	Sales&Marketing
Rekor Gıda Pazarlama A.Ş. (****)	-	-	-	43,9%	Sales&Marketing

- (*) The Company purchased 19.443.832 shares of Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş. for an amount of TRY 200.000.000 from Tayyar Family as of 6 May 2014.
- (**) The Company sold 12.570.003 shares of İstanbul Gıda Dış Ticaret A.Ş. for an amount of TRY 25.978.007 to Yıldız Holding A.Ş and Ülker Çikolata sold 1.245.000 shares of İstanbul Gıda Dış Ticaret A.Ş. for an amount of TRY 2.573.000 to Yıldız Holding A.Ş as of 6 May 2014.
- (***) The Company sold 875.500 shares of Birleşik Dış Ticaret A.Ş. for an amount of TRY 2.801.600 to Yıldız Holding A.Ş and Ülker Çikolata sold 124.500 shares of Birleşik Dış Ticaret A.Ş. for an amount of TRY 398.400 to Yıldız Holding A.Ş as of 6 May 2014.
- (****) Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş. sold 10.000.000 shares of Rekor Gıda Pazarlama A.Ş., for an amount of TRY 4.000.000 to Yıldız Holding A.Ş. as of 6 May 2014.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

1. ORGANIZATION AND OPERATIONS OF THE GROUP (cont'd)

Dividend Paid:

Group has decided to pay a dividend amount of TRY 133.000.000 (30 September 2013: TRY 150.000.000) in the current period. Dividend paid per share is TRY 0,39 (30 September 2013: TRY 0,44).

Approval of Financial Statements:

The Board of Directors has approved the financial statements and given authorization for the issuance on 6 November 2014. The General Assembly has the authority to amend/modify the financial statements.

2. BASIS OF PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

2.1 Basis of the presentation:

Financial reporting standards:

The Group companies, which operate in Turkey, keep their accounting books and their statutory financial statements in Turkish Lira in accordance with the Generally Accepted Accounting Principles in Turkey accepted by the Capital Markets Board (CMB), Turkish Commercial Code, Tax Legislation and the Uniform Chart of Accounts issued by the Ministry of Finance.

The consolidated financial statements are based on the statutory financial statements of the Group's subsidiaries and presented in TRY in accordance with CMB Financial Reporting Standards with certain adjustments and reclassifications for the purpose of fair presentation. Such adjustments are primarily related to application of consolidation accounting, accounting for business combinations, accounting for deferred taxes on temporary differences, accounting for employment termination benefits on an actuarial basis and accruals for various expenses. Except for the financial assets carried from their fair values and assets and liabilities included in business combinations application, financial statements are prepared on historical cost basis.

In accordance with the CMB's "Communiqué on Financial Reporting in Capital Market" Numbered II-14.1 (Communiqué), promulgated in the Official Gazette numbered 28676 dated June 13, 2013, effective from interim periods beginning after June 30, 2013, listed companies are required to prepare their financial statements in conformity with Turkey Accounting/Financial Reporting Standards (TAS/TFRS) as prescribed in the CMB Communiqué. The financial statements and explanatory notes are presented using the compulsory standard formats as published by the Communiqué.

In the scope of the CMB's "Communiqué on Financial Reporting in Capital Market" Numbered II-14.1 (Communiqué), the Group has prepared interim condensed consolidated financial statements in accordance with TAS 34, "Interim Financial Reporting". The financial statements and explanatory notes are presented using the compulsory standard formats as published by the Communiqué.

In accordance with the TAS, the entities are allowed to prepare a complete or condensed set of interim financial statements in accordance with TAS 34, "Interim Financial Reporting". In this respect, the Group has preferred to prepare condensed consolidated financial statements in the interim periods and prepared the aforementioned condensed consolidated financial statements in compliance with CMB Financial Reporting Standards.

Furthermore, in accordance with the Communiqué and announcements regarding the explanations of the Communiqué, guarantee pledge mortgage table, foreign currency position table, total export and total import amounts and hedging amount of total foreign currency liabilities are presented in the condensed consolidated financial statement disclosures.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

2. BASIS OF PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

2.2 Changes in the Accounting Policies:

Comparative Information and Reclassification of Prior Period Financial Statements

30 September 2013 Consolidated Income Statement	Previously reported	Classification of Raw Material Incentives	Change in CMB Classification (*)	Reclassified
			· /	
Revenue	1.978.409.277	-	-	1.978.409.277
Cost of Sales (-)	(1.524.992.318)	1.382.974	-	(1.523.609.344)
GROSS PROFIT FROM OPERATIONS	453.416.959	1.382.974	-	454.799.933
Research expenses (-)	(9.736.638)	-	-	(9.736.638)
Marketing expenses (-)	(177.434.936)	-	-	(177.434.936)
General administrative expenses (-)	(73.151.665)	-	-	(73.151.665)
Other income from main operations	133.860.757	(1.382.974)	(21.240.019)	111.237.764
Other expenses from main operations (-)	(119.074.020)			(119.074.020)
OPERATING PROFIT	207.880.457	-	(21.240.019)	186.640.438
Income from investing activities	152.975.845	-	21.240.019	174.215.864
Expenses from investing activities (-)	(21.568.649)	-		(21.568.649)
PROFIT BEFORE FINANCIAL INCOME AND				
EXPENSE	339.287.653	-	-	339.287.653
Financial income	23.863.530	-		23.863.530
Financial expense	(172.203.594)	-		(172.203.594)
PROFIT BEFORE TAX	190.947.589	-	-	190.947.589
Tax Expense	(38.946.622)	-	-	(38.946.622)
Income Tax Expense	(44.321.886)	-	-	(44.321.886)
Deferred Tax Expense	5.375.264	-	-	5.375.264
PROFIT FOR THE PERIOD	152.000.967	-	-	152.000.967

^(*) In accordance with CMB decision dated on 7 June 2013 at the numbered 20/670 meeting, the reclassifications were made by Group in the condensed consolidated income statements for the period ended 30 September 2013; interest income from financial services from operations amounting to TRY 15.481.830, rent revenues from operations amounting to TRY 5.758.189 presented under financial income in the previous year condensed consolidated financial statements are classified into income from investing activities.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

2. BASIS OF PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

2.3 Amendments in International Financial Reporting Standards

The new standards, amendments and interpretations which are effective for the financial statements as of 30 June 2014

- TAS 32 (amendment), "Financial instruments: Presentation", on offsetting financial assets and financial liabilities, is effective for annual periods beginning on or after 1 January 2014. The amendment updates the application guidance in TAS 32, 'Financial instruments: Presentation', to clarify some of the requirements for offsetting financial assets and financial liabilities on the balance sheet.
- TFRS 10, TFRS 12 and TAS 27 (amendments), "Consolidated financial statements": 'exceptions for the consolidation of subsidiaries'; is effective for annual periods beginning on or after 1 January 2014. These amendments mean that many funds and similar entities will be exempt from consolidating most of their subsidiaries. Instead they will measure them at fair value through profit or loss. The amendments give an exception to entities that meet an 'investment entity' definition and which display particular characteristics.
 - TAS 36 (amendments), "Impairment of assets" on recoverable amount disclosures is effective for annual periods beginning on or after 1 January 2014. This amendment addresses the disclosure of information about the recoverable amount of impaired assets if that amount is based on fair value less costs of disposal.
- TAS 39 (amendments) "Financial Instruments: Recognition and Measurement" "Novation of derivatives is effective for annual periods beginning on or after 1 January 2014. This amendment provides relief from discontinuing hedge accounting when novation of a hedging instrument to a central counterparty meets specified criteria.
- TFRIC 21 TAS 37, "Levies" is effective for annual periods beginning on or after 1 January 2014. This is an interpretation of TAS 37, 'Provisions, contingent liabilities and contingent assets'. TAS 37 sets out criteria for the recognition of a liability, one of which is the requirement for the entity to have a present obligation as a result of a past event (known as an obligating event). The interpretation clarifies that the obligating event that gives rise to a liability to pay a levy is the activity described in the relevant legislation that triggers the payment of the levy.

The new standards, amendments and interpretations introduced to the prior Financial Statements as of 30 June 2014, however will be effective after 1 July 2014

- TAS 19 (amendment), "Defined benefit plans", is effective for annual periods beginning on or after 1 July 2014. These narrow scope amendments apply to contributions from employees or third parties to defined benefit plans. The objective of the amendments is to simplify the accounting for contributions that are independent of the number of years of employee service, for example, employee contributions that are calculated according to a fixed percentage of salary.
- Annual improvements 2012; is effective for annual periods beginning on or after 1 July 2014. These amendments include changes from the 2010-12 cycle of the annual improvements project that affect 7 standards:
 - TFRS 2, "Share Based Payment"
 - TFRS 3, "Business Combination"
 - TFRS 8. "Operating Segments"
 - TFRS 13, "Fair value measurement"
 - TAS 16, "Tangible Assets and TAS/ 38, Intangible Assets"
 - TFRS 9, "Financial Instruments: TAS 37, Provisions, Contingent Assets and Liability"
 - TFRS 39, "Financial Instruments-Recognition and Measurement"

Annual improvements 2013; is effective for annual periods beginning on or after 1 July 2014. The amendments include changes from 2011-13 cycle of the annual improvements project that affect 4 standards:

- TFRS 1, "First Adoption of TFRS"
- TFRS 3, "Business Combinations"

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

2. BASIS OF PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (cont'd)

2.3 Amendments in International Financial Reporting Standards (cont'd)

- TFRS 13, "Fair Value Measurement"
- TAS 40, "Investment Properties"
- TFRS 11 (amendments), "Joint Arrangements", is effective for annual periods beginning on or after 1 July 2016. This amendment adds new guidance on how to account for the acquisition of an interest in a joint operation that constitutes a business. The amendments specify the appropriate accounting treatment for such acquisitions.
- TAS 16 and TAS 38 (amendments), "Tangible Assets", "Intangible Assets", is effective for annual periods beginning on or after 1 July 2016. In this amendment the IASB has clarified that the use of revenue based methods to calculate the depreciation of an asset is not appropriate because revenue generated by an activity that includes the use of an asset generally reflects factors other than the consumption of the economic benefits embodied in the asset.
- TFRS 14, "Regulatory deferral accounts", is effective for annual periods beginning on or after 1 July 2016. "Regulatory deferral accounts" permits first—time adopters to continue to recognize amounts related to rate regulation in accordance with their previous GAAP requirements when they adopt TFRS. However, to enhance comparability with entities that already apply TFRS and do not recognize such amounts, the standard requires that the effect of rate regulation must be presented separately from other items.
- TFRS 15, "Revenue from contracts with customers", is effective for annual periods beginning on or after 1 July 2017. The International Accounting Standards Board (IASB) and the US national standard-setter, the Financial Accounting Standards Board (FASB), initiated a joint project to clarify the principles for recognizing revenue and to develop a common revenue standard for IFRS and US GAAP. The objective of this Standard is to establish the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing and uncertainty of revenue and cash flows arising from a contract with a customer. The new model employs an asset and liability approach, rather than current revenue guidance focuses on an 'earnings processes.
- TFRS 9 "Financial instruments" classification and measurement; is effective for annual periods beginning on or after 1 January 2018. This standard on classification and measurement of financial assets and financial liabilities will replace TAS 39, "financial instruments: Recognition and measurement". TFRS 9 has two measurement categories: amortized cost and fair value. All equity instruments are measured at fair value. A debt instrument is measured at amortized cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest. For liabilities, the standard retains most of the TAS 39 requirements. These include amortized-cost accounting for most financial liabilities, with bifurcation of embedded derivatives. The main change is that, in cases where the fair value option is taken for financial liabilities, the part of a fair value change due to an entity's own credit risk is recorded in other comprehensive income rather than the income statement, unless this creates an accounting mismatch. This change will mainly affect financial institutions.
- Amendments to TFRS 9, "Financial instruments", regarding general hedge, is effective for annual periods beginning on or after 1 January 2018. These amendments to TFRS 9, "Financial instruments", bring into effect a substantial overhaul of hedge accounting that will allow entities to better reflect their risk management activities in the financial statements.

The Group assumed that the given amendments and interpretations has no material effect on the financial statements.

3. BUSINESS COMBINATIONS

Reform Gida Paz. San. ve Tic. A.Ş. fully consolidated with scope of transaction under common controls in the condensed consolidated financial statements as of 1 January 2013; it was acquired from Yildiz Holding A.Ş. on 18 February 2013. Public Oversight Accounting and Auditing Standards Authority ("POAASA") Turkish Accounting Standards Boards has published principal related with transaction under common control in official journal as of 21 July 2013. In accordance with the publication transaction under common controls has to perform in accordance with "Pooling of interest Method" by restating previous year financials. The Group has decided not to restate previous year financials by considering company size and monetary value of purchased company.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

4. SEGMENTAL INFORMATION

The Group's core business activities are manufacturing and marketing of biscuit, chocolate, chocolate coated biscuit, wafer, and cake. The reports reviewed routinely by the decision makers of the Group comprise consolidated amount and its results of Ülker Bisküvi Sanayi A.Ş. and its subsidiaries.

Since the Group has operations in only one production area and the decision makers use the consolidated financial statements, segmental reporting in accordance with TFRS 8 have not been provided in the accompanying condensed consolidated financial statements.

5. CASH AND CASH EQUIVALENTS

	30 September 2014	31 December 2013
Cash	21.269	25.443
Demand deposits	3.438.414	9.056.986
Time deposits (*)	339.081.106	1.154.745.091
Other liquid assets	-	555.638
•	342.540.789	1.164.383.158

^(*)Time deposits consist of overnight amounting to TRY 338.784.849 (31 December 2013: TRY 1.150.297.129).

Details of time deposits are shown below;

Currency Type	Weighted Average Effective Interest Rate (%)	Maturity	30 September 2014
TRY	7,84%	October 2014	2.760.734
USD	1,95%	October 2014	334.759.016
EUR	1,95%	October 2014	1.561.356
			339.081.106
	Weighted Average		
	Effective Interest		31 December
Currency Type	Rate (%)	Maturity	2013
TRY	8,94%	January-February 2014	145.138.421
USD	1,86%	January 2014	686.297.216
EUR	0,2%	January 2 <u>014</u>	323.309.454
			1.154.745.091
6. FINANCIAL INVESTMENTS		30 September	31 December
Short Term Financial Investments:		2014	2013
Financial investments are classified at FVTPL		770.107	611.476
		770.107	611.476
The Company's short-term financial investments	consist various securitie	s.	
		30 September	31 December
Long Term Financial Investments:		2014	2013
Available for sales financial assets		467.345.369	464.661.239
		467.345.369	464.661.239

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

6. FINANCIAL INVESTMENTS (cont'd)

Long Term Available for Sale Financial Investments	Share %	30 September 2014	Share %	31 December 2013
				
G New, Inc	19,23%	148.876.952	19,23%	148.876.952
Godiva Belgium BVBA	19,23%	289.715.942	19,23%	289.715.942
BİM Birleşik Mağazalar A.Ş.	0,20%	28.552.357	0,20%	25.825.951
Other		200.118		242.394
		467.345.369		464.661.239

Available for sale financial assets are presented at their fair values. As of 30 September 2014 the difference of TRY 257.045.237 (2013: TRY 254.670.905) in the fair values of such assets has directly been presented in other comprehensive income under equity.

As the expected value gaps for available for sale financial assets of TRY 200.118 (2013: TRY 242.394) that are not traded in an active market are high and expected values are not reliably measured, these have been presented at historical cost in accompanying condensed consolidated financial statements.

7. FINANCIAL LIABILITIES

	30 September 2014	31 December 2013
Short Term Borrowings	100.698.813	150.942.003
Short Term Portion of Long Term Borrowings	733.841.163	1.098.791.211
Long Term Borrowings	-	9.851.176
	834.539.976	1.259.584.390
Short Term Borrowings	30 September 2014	31 December 2013
Bank Loans	3.357.296	150.942.003
Borrowings From Related Parties (note 21)	97.341.517	
	100.698.813	150.942.003
Short Term Portion of Long Term Borrowings	30 September 2014	31 December 2013
Bank Loans	733.600.620	1.093.534.286
Financial Lease Payables	240.543	5.256.925
	733.841.163	1.098.791.211
Long Term Borrowings	30 September 2014	31 December 2013
Bank Loans	-	9.788.823
Financial Lease Payables		62.353
		9.851.176

Details of Group's syndication loans are as follows;

Participation loan consists of two credit trenches which are USD 138.280.000 and EUR 134.850.000 14 international banks joined the participation. Effective interest rate for both credit trenches is libor + 3,4% and the maturity date is November 2014. Principal payments of the loans are paid with interest, semi-annually at the end of the period.

The covenants which belong to participation credits are as follows;

- a) <u>Leverage:</u> The ratio of the consolidated net loan at the end of the balance sheet date to the consolidated last twelve month EBITDA in the valid period should not be over the ratio of 3 to 1.
- b) <u>Interest Coverage:</u> Consolidated interest coverage ratio of the Group for the balance sheet date should be at least 3 to 1.

In current period, condensed consolidated financial statements of the Group comply with the covenants of the bank loan agreement.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

7. FINANCIAL LIABILITIES (cont'd)

7. FINANC	TAL LIABILITIES (cont'd)			
30 September	er 2014			
Currency TRY USD EUR	Maturity Spot October 2014-April 2015 October 2014-April 2015	Effective Weighted Average Interest Rate (%) Spot 3,26% 3,79%	Short Term 3.357.296 416.369.733 414.572.404 834.299.433	Long Term - - - -
31 December	r 2013	-	031.277.133	
51 December	1 2015	Effective		
Currency		Weighted Average Interest Rate		
	<u>Maturity</u>	(%)	Short Term	Long Term
TRY	Spot	Spot	4.370.289	-
EUR USD	February 2014-November 2014 February 2014-April 2015	2,89% 3,92%	783.805.171 456.300.829	9.788.823
USD	rebluary 2014-April 2013	3,9270 _	1.244.476.289	9.788.823
(TD)	1. 1. 6.1. 6. 1.11	=		
The maturity	detail of the financial borrowings is as foll	ows:	30 September 2014	31 December 2013
	within 1 year within 1-2 years		834.299.433	1.244.476.289 9.788.823
•	·		834.299.433	1.254.265.112
a) The detail	of short term financial lease payables is as	follows:		
	ı Financial Lease Payables		30 September 2014	31 December 2013
	ase payables		257.553	5.376.313
Deferred fir	nancial lease payables (-)		(17.010) 240.543	(119.388) 5.256.925
			240.545	5.250.925
	of long term financial lease payables is as Financial Lease Payables	follows:	30 September 2014	31 December 2013
E: '11				60.505
	ase payables ancial lease payables (-)		-	69.587 (7.234)
Deterred IIII	ianciai lease payables (-)			62.353
The maturity	detail of the financial lease payables is as t	follows:		
			30 September 2014	31 December 2013
	within 1 year within 1-5 years		240.543	5.256.925 62.353
1	·		240.543	5.319.278

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

8. TRADE RECEIVABLES AND PAYABLES		
	30 September	31 December
	2014	2013
Due from Related Parties		
Due from related parties (Note 21)	605.683.405	446.815.319
	605.683.405	446.815.319
Other Trade Receivables		
Trade receivables	38.998.495	175.211.204
Notes receivables	2.384.007	34.664.418
Provision for doubtful receivables	(1.532.442)	(6.222.135)
Discount of trade receivables (-)	(635.814)	(1.698.738)
	39.214.246	201.954.749
Total Short Term Trade Receivables	644.897.651	648.770.068

Trade receivables are disclosed at discounted net realizable value using the effective yield method. Net realizable value has been calculated over discount rate of 9,5 % (31 December 2013: 8,0%) based on the Group's cash sales. The provision for trade receivables is provided for based on the estimated irrecoverable amounts from the sale of goods, determined by reference to past default experience.

The movement of the allowance for doubtful receivables as of 30 September 2014 and 30 September 2013 is as follows:

	1 January- 30 September 2014	1 January- 30 September 2013
Opening balance	(6.222.135)	(6.494.812)
Charge for the period	(475.245)	(110.030)
Foreign Exchange Difference	-	(11.085)
Provision reversal	3.642.593	238.329
Disposal from scope of consolidation	1.517.374	-
Collections	4.971	108.647
Closing balance	(1.532.442)	(6.268.951)
Short Term Trade Payables	30 September 2014	31 December 2013
Due to related parties (Note 21)	212.162.684	273.321.957
Other Trade payables	200.882.728	235.142.437
	413.045.412	508.464.394

Trade payables are disclosed at discounted net realizable value using the effective yield method. Net realizable value has been calculated over discount rate of 9,5% (31 December 2013: 8,0%) based on the Group's cash sales.

9. OTHER RECEIVABLES AND PAYABLES

	30 September 2014	31 December 2013
Short Term Other Receivables	·	
Due from related parties (Note 21)	223.586	3.417.357
Short term other receivables	366.439	16.860.567
	590.025	20.277.924
Other Short Term Receivables		
VAT Receivables	-	6.886.001
Receivables from employees	2.619	318.056
Deposits and guarantees given	291.530	352.662
Receivables from tangible sales	-	8.872.318
Other	72.290	431.530
	366.439	16.860.567

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

9. OTHER RECEIVABLES AND PAYABLES (cont'd)

Other Long Term Receivables	30 September 2014	31 December 2013
Deposits and guarantees given	175.288 175.288	161.464 161.464
Other Payables	30 September 2014	31 June 2013
Due from related parties (Note 21) Other short-term payables	1.381.014 1.381.014	86.857 344.940 431.797

10. INVENTORIES

Inventory details are as follows:

inventory details are as follows.	30 September 2014	31 December 2013
Raw materials	107.896.165	79.436.010
Work in progress	11.716.342	8.341.511
Finished goods	125.774.419	101.979.209
Trade goods	418.828	2.771.255
Other inventories	13.586.670	10.584.281
Allowance for impairment on inventory (-)	(3.654.856)	(4.790.533)
•	255.737.568	198.321.733

Inventory is presented on cost value and allowance for impairment is booked for inventory valuing lower than cost.

The movement of allowance for impairment on inventory for the periods ended 30 September 2014 and 30 September 2013 are below:

	1 January- 30 September 2014	1 January- 30 September 2013
Opening balance	(4.790.533)	(9.147.920)
Charge for the period	(793.102)	(447.986)
Used allowance	1.928.779	4.596.573
Closing balance	(3.654.856)	(4.999.333)

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

11. INVESTMENT PROPERTIES

	1 January-	1 January-
	30 September	30 September
	2014	2013
Opening balance	10.035.000	30.460.000
Disposal	-	(20.645.000)
Closing balance	10.035.000	9.815.000

The fair value of the Group's investment properties at 31 December 2013 has been calculated on the basis of a valuation carried out at that date by 6 December 2013, by independent values not related to the Group. EVA Gayrimenkul Değerleme Danışmanlık A.Ş. is one of the accredited independent values by Capital Markets Board of Turkey, and has appropriate qualifications and recent experience in the valuation of properties in the relevant locations. The valuation, which conforms to International Valuation Standards, was arrived at by reference to market evidence of transaction prices for similar properties.

The rent income earned by the Group from its investment properties, which are buildings, amounting to TRY 820.371 (30 September 2013: TRY 446.577) within the current period. Direct operating expenses arising from the investment properties in the current period amounting to TRY 36.422 (30 September 2013: TRY 83.632).

The Group has sold the warehouse that is located Bayrampaşa/İstanbul, amounting to TL 17.118.094 on 30 July 2013.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

12. TANGIBLE ASSETS

Movement of tangible assets between 1 January - 30 September 2014 are as follows:

Cost	1 January 2014	Addition	Disposal	Transfers (Note 13)	Disposal from the scope of consolidation	30 September 2014
Land	3.376.659	10.000	-	_	-	3.386.659
Land improvements	6.484.021	329.525	-	99.213	-	6.912.759
Buildings	242.703.970	244.158	(2.323.680)	361.136	(222.589)	240.762.995
Machinery, plant and equipment	734.359.082	15.992.869	(219.302)	21.865.567	-	771.998.216
Vehicles	1.109.054	55.847	(36.401)	-	(230.970)	897.530
Furniture and fixtures	44.252.580	1.352.209	(24.959)	706.753	(2.159.201)	44.127.382
Leasehold improvements	16.013.470	374.439	· -	-	(775.373)	15.612.536
Other tangible assets	1.396	-	-	-	-	1.396
Construction in progress	19.427.468	40.073.489	(658.983)	(23.477.016)	-	35.364.958
	1.067.727.700	58.432.536	(3.263.325)	(444.347)	(3.388.133)	1.119.064.431
					Disposal from the	
Accumulated Depreciation	1 January 2014	Charge for the period	Disposal	Transfers (Note 13)	scope of consolidation	30 September 2014
Land improvements	(2.563.708)	(243.232)	-	-	-	(2.806.940)
Buildings	(67.163.827)	(5.359.239)	398.517	-	370	(72.124.179)
Machinery, plant and equipment	(416.809.998)	(32.648.119)	110.771	-	=	(449.347.346)
Vehicles	(1.051.259)	(62.716)	33.294	-	230.970	(849.711)
Furniture and fixtures	(37.275.765)	(1.879.467)	12.962	-	1.871.396	(37.270.874)
Leasehold improvements	(10.303.640)	(657.983)	-	-	747.338	(10.214.285)
Other tangible assets	(1.396)	-	-	-	=	(1.396)
	(535.169.593)	(40.850.756)	555.544	-	2.850.074	(572.614.731)
Net Book Value	532.558.107				_	546.449.700

From depreciation and amortization expenses, TRY 37.386.173 (30 September 2013: TRY 34.134.669) is included in cost of goods sold, TRY 246.040 (30 September 2013: TRY 159.308) is included in research expenses, TRY 1.591.358 (30 September 2013: TRY 1.908.447) is included in marketing expenses and TRY 1.920.834 (30 September 2013: TRY 2.182.808) is included in general administrative expenses.

In the related period there is no fixed assets acquired through financial leasing.

There is no collateral or mortgage on fixed assets.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

12. TANGIBLE ASSETS (cont'd)

Movement of tangible assets between 1 January - 30 September 2013 are as follows:

Cost	1 January 2013	Addition	Disposal	Addition to the scope of consolidation	Transfers (Note 13)	30 September 2013
Land	8.376.659	-	(5.000.000)	-	-	3.376.659
Land improvements	6.247.149	151.435	-	-	18.529	6.417.113
Buildings	251.413.316	11.160	(9.167.990)	-	3.629.016	245.885.502
Machinery, plant and equipment	680.430.113	17.396.395	(8.075.304)	3.201.591	20.135.051	713.087.846
Vehicles	1.134.736	26.909	(38.782)	-	-	1.122.863
Furniture and fixtures	43.157.448	1.261.495	(1.445.541)	-	603.594	43.576.996
Leasehold improvements	19.655.248	1.048.091	(1.250.721)	-	-	19.452.618
Other tangible assets	1.396	-	-	-	-	1.396
Construction in progress	12.654.101	29.142.484	(264.187)	-	(24.619.979)	16.912.419
	1.023.070.166	49.037.969	(25.242.525)	3.201.591	(233.789)	1.049.833.412
Accumulated Depreciation	1 January 2013	Charge for the period	Disposal	Addition to scope of consolidation	Transfers (Note 13)	30 September 2013
Land improvements	(2.254.779)	(230.918)	-	-	-	(2.485.697)
Buildings	(61.205.894)	(5.561.117)	487.236	-	-	(66.279.775)
Machinery, plant and equipment	(386.987.793)	(30.393.425)	4.429.924	(817.420)	-	(413.768.714)
Vehicles	(1.040.694)	(47.555)	38.560	-	-	(1.049.689)
Furniture and fixtures	(36.847.749)	(1.358.048)	1.361.074	-	-	(36.844.723)

(683.232)

(38.274.295)

292.948

6.609.742

(817.420)

(10.819.237)

(531.249.231)

518.584.181

(1.396)

In the related period there is no fixed assets acquired through financial leasing.

There is no collateral or mortgage on fixed assets.

Leasehold improvements

Other tangible assets

Net Book Value

(10.428.953)

(498.767.258)

524.302.908

(1.396)

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

12. TANGIBLE ASSETS (cont'd)

The useful lives of tangible assets are as follows:

	Useful Life
Land improvements	10 - 50 years
Buildings	25 - 50 years
Machinery, plant and equipment	4 - 15 years
Vehicles	4 - 10 years
Furniture and fixtures	3 - 10 years
Other tangible assets	4 - 10 years
Leasehold improvements	During rent period

13. INTANGIBLE ASSETS

Movement of intangible assets between 1 January - 30 September 2014 are as follows:

Cost	1 January 2014	Addition	Transfers (Note 12)	Disposal from the scope of consolidation	30 September 2014
Rights	2.157.120	315.806	444.347	(1.177.933)	1.739.340
Other intangible assets	1.141.475	41.177	-	(281.254)	901.398
	3.298.595	356.983	444.347	(1.459.187)	2.640.738
Accumulated amortization	1 January 2014	Charge for the period	Transfers (Note 12)	Disposal from the scope of consolidation	30 September 2014
Rights	(1.668.333)	(178.866)	-	1.111.357	(735.842)
Other intangible assets	(838.673)	(114.783)	-	279.959	(673.497)
	(2.507.006)	(293.649)	-	1.391.316	(1.409.339)
Net Value	791.589			_ =	1.231.399

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

13. INTANGIBLE ASSETS (cont'd)

Movement of intangible assets between 1 January - 30 September 2013 are as follows:

Cost	1 January 2013	Addition	Disposal	Transfer (Note 12)	30 September 2013
					_
Rights	1.895.364	3.808	-	230.657	2.129.829
Other intangible assets	1.047.549	41.944	(34.952)	3.132	1.057.673
	2.942.913	45.752	(34.952)	233.789	3.187.502
Accumulated amortization	1 January 2013	Charge for the period	Disposal	Transfer (Note 12)	30 September 2013
Rights	(1.535.567)	(92.347)	-	-	(1.627.914)
Other intangible assets	(732.907)	(90.590)	17.438	-	(806.059)
	(2.268.474)	(182.937)	17.438		(2.433.973)
Net Book Value	674.439			_	753.529

The intangible assets are amortized on a straight-line basis over their estimated useful lives.

	Useful
	Life
Rights	2 - 15 years
Other intangible assets	2 - 12 years

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

14. CONTINGENT ASSETS AND LIABILITIES

Guarantees given:

(Foreign currency amounts are shown in original currencies)

		30 September 2014		31 December 2013		3	
		Total	TRY	USD	Total	TRY	USD
A)	CPM's given in the name of own legal personality	79.193.677	79.045.776	64.900	60.142.454	60.003.938	64.900
B)	CPM's given on behalf of the fully consolidated companies	-	-	-	-	-	-
C)	CPM's given on behalf of third parties for ordinary course of business	-	-	-	-	-	-
D)	Total amount of other GPMs	-	-	-	-	-	-
	 Total amount GPMs given on behalf of the majority shareholders 	-	-	-	-	-	-
	ii. Total amount of GPMs given to on behalf of other group companies which are not in scope of B and C	-	-	-	-	-	-
	iii. Total amount of GPMs given on behalf of third parties which are not in scope of consolidation	-	-	-	-	-	-
	Total	79.193.677	79.045.776	64.900	60.142.454	60.003.938	64.900

15. REVENUE AND COST OF SALES

The detail of the operational income is as follows:

	1 January- 30 September 2014	1 July- 30 September 2014	1 January- 30 September 2013	1 July- 30 September 2013
Domestic sales	2.415.267.214	811.654.639	2.256.420.194	752.805.113
Export sales	376.902.950	92.822.918	370.021.148	120.193.683
Sales returns and discounts (-)	(668.984.776)	(231.822.476)	(648.032.065)	(220.869.006)
Revenue	2.123.185.388	672.655.081	1.978.409.277	652.129.790
Cost of goods sold (-)	(1.658.200.906)	(544.818.767)	(1.447.308.285)	(484.269.685)
Cost of trade goods sold (-)	(23.633.186)	(2.384.803)	(76.301.059)	(23.238.329)
Cost of Sales	(1.681.834.092)	(547.203.570)	(1.523.609.344)	(507.508.014)
Gross Profit	441.351.296	125.451.511	454.799.933	144.621.776

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

16. EXPENSES BY NATURE

The detail of operating expenses is as follows;

	1 January-	1 July-	1 January-	1 July-
	30 September	30 September	30 September	30 September
-	2014	2014	2013	2013
Research Expenses				
Materials used	(6.273.367)	(1.880.134)	(4.914.694)	(722.879)
Personnel expenses	(1.122.878)	(159.582)	(1.585.035)	(250.914)
Depreciation and amortization expenses	(246.040)	(94.628)	(159.308)	(60.764)
Other	(2.525.774)	(339.136)	(3.077.601)	(912.425)
	(10.168.059)	(2.473.480)	(9.736.638)	(1.946.982)
Marketing Expenses	_	_		
Marketing operation expenses	(148.931.223)	(41.369.587)	(143.539.688)	(46.419.395)
Personnel expenses	(14.587.445)	(3.564.117)	(20.278.831)	(6.359.551)
Depreciation and amortization expenses	(1.591.358)	(560.954)	(1.980.447)	(793.472)
Rent expenses	(1.065.078)	(182.131)	(3.106.351)	(1.178.254)
Other	(3.477.749)	(447.349)	(8.529.619)	(2.384.007)
	(169.652.853)	(46.124.138)	(177.434.936)	(57.134.679)
General Administrative Expenses				
Personnel expenses	(28.951.714)	(7.453.705)	(29.865.571)	(9.803.892)
Operating expenses (*)	(28.553.085)	(8.152.401)	(30.063.545)	(9.546.780)
Depreciation and amortization expenses	(1.920.834)	(657.130)	(2.182.808)	(726.209)
Consultancy expenses	(285.109)	(70.211)	(362.140)	(110.939)
Other	(7.570.626)	(1.954.342)	(10.677.601)	(3.258.284)
- -	(67.281.368)	(18.287.789)	(73.151.665)	(23.446.104)

^(*)The operating expenses of the Group mainly comprise management support, information technology and administration expenses that are charged by Yıldız Holding.

17. FINANCIAL INCOME

	1 January-	1 July-	1 January-	1 July-
	30 September	30 September	30 September	30 September
	2014	2014	2013	2013
Foreign exchange and interest gain from financing	59.481.556	15.361.064	23.863.530	8.420.816
Ç	59.481.556	15.361.064	23.863.530	8.420.816
18. FINANCIAL EXPENSES	1 January-	1 July-	1 January-	1 July-
	30 September	30 September	30 September	30 September
	2014	2014	2013	2013
Foreign exchange and interest losses from financing Other	(153.477.098)	(53.489.008)	(171.217.439)	(73.235.043)
	(1.274.853)	(544.339)	(986.155)	(375.076)
	(154.751.951)	(54.033.347)	(172.203.594)	(73.610.119)

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

19. TAX ASSET AND LIABILITIES (INCLUDING DEFERRED TAX ASSET AND LIABILITIES)

The Group accounts deferred tax assets and liabilities for temporary timing differences rooted from differences between legal financial statements and financial statements prepared in accordance with TFRS. The differences in question are caused generally by the fact that some profit and loss accounts come up in different periods in legal financial statements and financial statements prepared in accordance with TFRS. These differences are specified below.

Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, deferred tax positions of the firms with deferred tax assets is netted against those with deferred tax liabilities and reflected on a separate-entity basis.

The rate applied in the calculation of deferred tax assets and liabilities is 20% (2013: 20%).

Deferred tax bases:

	Deferred tax	(assets)	Deferred tax	liabilities
·	30 September 2014	31 December 2013	30 September 2014	31 December 2013
Useful life and valuation differences on tangible				
and intangible assets	-	-	142.554.663	143.786.202
Valuation differences of investment properties	-	-	9.390.810	9.349.692
Marketable securities valuation differences	-	-	270.237.240	268.551.100
Profit margin elimination on inventory	(22.697)	(272.145)	-	-
Discount of trade receivables / payables (net)	(3.052.298)	(954.861)	-	-
Allowance of employee termination benefits	(25.909.016)	(23.380.797)	-	-
Allowance for doubtful receivables	(644.681)	(5.813.744)	-	-
Previous year losses	(9.640.520)	(14.867.955)	-	-
Provision for lawsuits	(3.718.417)	(3.772.686)	-	-
Other	(15.365.057)	(15.742.974)	-	-
	(58.352.686)	(64.805.162)	422.182.713	421.686.994

Deferred tax (assets) / liabilities:

	Deferred tax (assets)		Deferred tax liabilities	
•	30 September	31 December	30 September	31 December
	2014	2013	2014	2013
Useful life and valuation differences on tangible				
and intangible assets	-	-	28.510.933	28.757.239
Valuation differences of investment properties	-	-	469.541	467.485
Marketable securities valuation differences	-	-	13.511.862	13.427.555
Profit margin elimination on inventory	(4.539)	(54.429)	-	-
Discount of trade receivables / payables (net)	(610.461)	(190.973)	-	-
Allowance for employee termination benefits	(5.181.804)	(4.676.160)	-	-
Allowance for doubtful receivables	(128.936)	(1.162.749)	-	-
Previous year losses	(1.928.104)	(2.973.591)	-	-
Provision for lawsuits	(743.684)	(754.537)	-	-
Investment incentive	(11.342.199)	-		-
Other	(3.073.012)	(3.148.595)	<u>-</u>	
	(23.012.739)	(12.961.034)	42.492.336	42.652.279
=				

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

19. TAX ASSET AND LIABILITIES (INCLUDING DEFERRED TAX ASSET AND LIABILITIES) (cont'd)

Movement of Deferred Tax Liabilities:	1 January - 30 September 2014	1 January- 30 September 2013
Opening balance	29.691.245	22.693.528
Amendment in scope with consolidation	2.314.079	-
Taxes netted against funds recognized under equity	436.962	(130.966)
Deferred tax gain	(12.962.689)	(5.375.264)
	19.479.597	17.187.298

The Group calculated deferred tax assets of TRY 9.640.520 for deductible financial losses in the condensed consolidated financial statements for the current year (31 December 2013: TRY 14.867.955). The maturities of these losses are as follows:

	30 September 2014	31 December 2013
2016	4.450.256	3.060.807
2017	5.190.264	6.616.884
2018		5.190.264
Total	9.640.520	14.867.955

Corporate Tax

The Company and its Turkish subsidiaries are subject to Turkish corporate taxes. Provision is made in the accompanying financial statements for the estimated charge based on the Group's results for the period.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding back non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

The effective tax rate in 30 September 2014 is 20% (31 December 2013: 20%).

In Turkey, advance tax returns are filed on a quarterly basis. The advance corporate income tax rate is 20% in 2014 (31 December 2013: 20%).

Losses are allowed to be carried five years maximum to be deducted from the taxable profit of the following years. However, losses occurred cannot be deducted from the profit occurred in the prior years retroactively.

In Turkey, there is no procedure for a final and definitive agreement on tax assessments. Companies file their tax returns between 1st-25th of April following the close of the accounting year to which they relate. The companies with special accounting periods file their tax returns between 1st-25th of fourth month after fiscal year end. Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years.

Income withholding tax

In addition to corporate taxes, companies should also calculate income withholding taxes and funds surcharge on any dividends distributed, except for companies receiving dividends who are Turkish residents and Turkish branches of foreign companies. Income withholding tax applied in between 24 April 2003 - 22 July 2006 is 10% and commencing from 23 July 2006, this rate has been changed to 15% upon the Council of Ministers' Resolution No: 2006/10731. Undistributed dividends incorporated in share capital are not subject to income withholding tax.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

19. TAX ASSET AND LIABILITIES (INCLUDING DEFERRED TAX ASSET AND LIABILITIES) (cont'd)

Provision for taxation as of 30 September 2014 and 31 December 2013 are as follows:

	30 September 2014	31 December 2013
Current year corporate tax provision	(32.463.604)	(51.860.071)
Prepaid tax and funds Taxation in the balance sheet	19.560.379 (12.903.225)	40.388.418 (11.471.653)
	1 January - 30 September 2014	1 January - 30 September 2013
Current year corporate tax expense	32.463.604	44.321.886
Deferred tax income Taxation in the statement of income	(12.962.689) 19.500.915	(5.375.264) 38.946.622

20. EARNINGS PER SHARE

A summary of the Group's weighted average number of shares outstanding as of 30 September 2014 and 30 September 2013 and computation of earnings per share set out here as follows:

	1 January - 30 September 2014	1 January - 30 September 2013
Weighted average number of common stock outstanding	34.200.000.000	34.200.000.000
Net profit	155.248.087	122.568.825
Earnings Per Share (TRY 1 par value each)	0,45	0,36

21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES

a) The detail of receivables from related parties is as follows:

	30 September	31 December 2013
Trade receivables	605.683.405	446.815.319
Non-trade receivables	223.586	3.417.357
	605.906.991	450.232.676

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)

The detail of receivables from related parties is as follows:

	30 September 2014		31 Decemb	er 2013
	Trade	Non-Trade	Trade	Non-Trade
Principle Shareholders				
Yıldız Holding A.Ş.	-	-	-	905.012
Other Companies Controlled by the Principle Share	eholders			
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	289.561.815	-	220.716.160	-
Pasifik Tük. Ürün. Satış Ve Ticaret A.Ş.	150.591.249	-	131.726.060	-
Teközel Gıda T.Sağ. Mrk. Hiz. San. Tic. A.Ş.	43.244.205	-	39.587.999	-
Rekor Gıda Paz. San. ve Tic. A.Ş. (*)	36.208.876	-	-	-
İstanbul Gıda Dış Tic. A.Ş. (*)	27.906.553	-	-	-
Hamle Company Ltd. (Kazakistan)	5.094.336	-	5.875.462	2.321.999
Natura Gıda San. ve Tic. A.Ş.	3.676.020	223.586	3.923.095	-
Birleşik Dış Ticaret A.Ş. (*)	501.789	-	-	-
Egal Gıda Mad.San. ve Tic.A.Ş.	400.030	-	-	-
Other	48.498.532		44.986.543	190.346
	605.683.405	223.586	446.815.319	3.417.357

^(*) The Company has handed over all of the shares of İstanbul Gıda Dış Ticaret A.Ş., Rekor Gıda Paz. San. ve Tic. A.Ş. and Birleşik Dış Ticaret A.Ş. to Yıldız Holding A.Ş. as of 6 May 2014.

The Group's trade receivables from related parties mainly arise from sales to Horizon Hızlı Tüketim Ürünleri Pazarlama Satış ve Tic. A.Ş.and Pasifik Tük. Ürün. Satış ve Ticaret A.Ş. those make the sale and distribution of products throughout Turkey, İstanbul Gıda Dış Ticaret A.Ş. and Birleşik Dış Ticaret A.Ş those make the sale and distribution of products for Export Sales.

30 September

31 December

b) The detail of payables to related parties is as follows:

Trada navahlas

Trade payables		21	2.162.684	273.321.957
Non-trade payables			-	86.857
		21	2.162.684	273.408.814
	30 Septemb	er 2014	31 Decemb	er 2013
	Trade	Non-Trade	Trade	Non-Trade
Principle Shareholders				
Yıldız Holding A.Ş.	8.436.241	-	9.796.437	-
Other Companies Controlled by the Princip	le Shareholders			
Önem Gıda San. ve Tic. A.Ş.	147.155.072	_	166.622.151	-
Besler Gıda ve Kimya San. Tic. A.Ş.	30.593.655	-	51.189.561	-
Marsa Yağ San. ve Tic. A.Ş.	14.540.096	_	18.007.874	-
Ak Gıda San. ve Tic. A.Ş.	3.310.636	-	7.138.768	-
Northstar Innovation A.Ş.	1.154.217	-	4.645.202	-
Other	6.972.767	_	15.921.964	86.857
	212.162.684		273.321.957	86.857

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)

b) The detail of payables to related parties is as follows (cont'd):

Detail of due to related parties as loan payables is as follow:

	30 September 2014	31 December 2013
Yıldız Holding A.Ş.	2.989.360	-
Eksper Gıda Pazarlama San. ve Tic. A.Ş.	71.563.157	-
İstanbul Gıda Dış Tic. A.Ş.	22.789.000	-
	97.341.517	-

c) The detail of purchases from and sales to related parties is as follows:

	1 January - 30 September 2014		1 July - 30 September 2014		1 January - 30 September 2013		1 July - 30 September 2013	
	Purchases	Sales	Purchases	Sales	Purchases	Sales	Purchases	Sales
Other Companies Controlled by the Principle Shareholders								
Önem Gıda San. ve Tic. A.Ş.	604.130.347	631.486	205.570.423	-	499.264.999	467.553	174.893.240	11.846
Besler Gıda ve Kimya San. ve Tic. A.Ş.	101.988.772	15.485	32.382.043	-	129.575.194	15.049	44.870.245	3.286
Marsa Yağ San. ve Tic. A.Ş.	46.525.483	=	13.594.742	-	40.590.972	-	15.399.348	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	24.344	995.223.090	24.344	340.537.184	-	872.718.687	-	292.698.029
Ak Gıda San. ve Tic. A.Ş.	23.885.917	57.810	6.803.065	39.726	28.441.799	37.870	11.263.430	17.557
Pendik Nişasta San. A.Ş.	12.450.766	-	2.305.772	-	12.047.413	-	3.711.315	-
İstanbul Gıda Dış Tic. A.Ş.(*)	-	81.395.067	-	41.518.490	-	-	-	-
Hamle Company (Kazakistan)	-	3.804.662	-	6.576	-	7.134.857	-	1.971.477
Teközel Gıda Tem. Sağ. Mark. Hizm. A.Ş.	-	135.855.010	-	40.096.710	-	115.794.037	-	34.366.147
Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.	4.369	447.975.824	-	157.504.085	-	400.591.656	=	132.084.618
Other	18.933.438	148.192.999	1.277.174	35.875.521	46.604.649	55.641.553	13.861.450	20.989.226
	807.943.436	1.813.151.433	261.957.563	615.578.292	756.525.026	1.452.401.262	263.999.028	482.142.186

^(*) The Company has handed over all of the shares of İstanbul Gıda Dış Ticaret A.Ş. to Yıldız Holding A.Ş. as of 6 May 2014.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)

d) The detail of income and expenses pertaining to interest, rent and services arising from transactions with related parties is as follows:

Foreign

Foreign

For the nine months interim period ended on 30 September 2014;

					Foreign Exchange and	Exchange and
	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income	Interest Expense
Principle Shareholders						
Yıldız Holding A.Ş.	102.772	(4.079)	436.294	(83.139.791)	143.523.398	(12.498.741)
Other Companies						
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	(593)	9.286	(1.620.164)	3.309	(346.584)
Hüner Pazarlama San. ve Tic. A.Ş.	488.769	-	294.101	(139.270)	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	20.432	(12.380)	507.404	(1.049.445)	-	(599.403)
Önem Gıda San. ve Tic. A.Ş.	1.280.710	(4.745)	3.193.131	(1.215.531)	95.104	(823.210)
Marsa Yağ San. ve Tic. A.Ş.	4.028	-	619	-	-	(823.152)
Northstar Innovation A.Ş.	70.396	-	53.711	(8.981.471)	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	-	(419.703)	-	(149.056)	-	-
Natura Gıda San. ve Tic. A.Ş.	130.704	-	366.400	(415.958)	160.189	(9)
Other	568.395	(8.093)	1.665.174	(4.091.172)	4.540.390	(8.397.522)
	2.666.206	(449.593)	6.526.120	(100.801.858)	148.322.390	(23.488.621)

For the three months interim period between 1 July - 30 September 2014;

					Foreign Exchange and	Foreign Exchange and
	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income	Interest Expense
Principle Shareholders		•		•		
Yıldız Holding A.Ş.	37.170	-	147.481	(24.551.696)	100.080.146	(2.025.099)
Other Companies						
Besler Gıda ve Kimya San. ve Tic. A.Ş.	-	-	8.786	(588.252)	3.309	(282.465)
Hüner Pazarlama San. ve Tic. A.Ş.	173.915	-	63.638	(54.282)	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	4.700	(8.636)	454.715	(348.648)	-	(387.635)
Önem Gıda San. ve Tic. A.Ş.	889.375	(1.605)	948.942	(298.161)	-	(205.002)
Marsa Yağ San. ve Tic. A.Ş.	1.530	-	-	-	-	(7.307)
Northstar Innovation A.Ş.	22.394	-	5.274	(732.496)	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	-	(71.992)	-	(27.667)	-	-
Natura Gıda San. ve Tic. A.Ş.	-	-	151.873	-	33.034	-
Other	84.489	-	-	(369.540)	650.651	(6.626.344)
	1.213.573	(82.233)	1.780.709	(26.970.742)	100.767.140	(9.533.852)

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

21. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (cont'd)

d) The detail of income and expenses pertaining to interest, rent and services arising from transactions with related parties is as follows:

For the nine months interim period ended on 30 September 2013;

	T	T	, a .	a .	Foreign Exchange and	Foreign Exchange and
	Rent Income	Rent Expense	Service Income	Service Expense	Interest Income	Interest Expense
Principle Shareholders		•		•		
Yıldız Holding A.Ş.	88.276	(7.299)	227.739	(74.008.671)	136.487.191	(2.599.224)
Other Companies						
Hero Gıda Sanayi ve Tic.A.Ş. Hüner Pazarlama San. ve Tic.	1.200	-	1.416.083	(312.413)	-	-
A.Ş. Horizon Hızlı Tük. Ür. Paz.	432.001	(255)	317.232	(7.513)	-	-
Sat. ve Tic. A.Ş.	40.345	(27.572)	264.436	(576.888)	-	-
Önem Gıda San. ve Tic. A.Ş.	892.423	(4.500)	3.485.820	(86.702)	4.189	(422.851)
Northstar Innovation A.Ş. İzsal Gayrimenkul Geliştirme	75.354	-	45.703	(8.818.269)	-	-
A.Ş.	-	(709.092)	-	(260.606)	-	-
Other	674.167	(3.912)	1.098.604	(5.396.375)	9.177.788	(1.817.063)
	2.203.766	(752.630)	6.855.617	(89.467.437)	145.669.168	(4.839.138)

For the three months interim period between 1 July - 30 September 2013;

	Rent Income	Rent Expense	Service Income	Service Expense	Foreign Exchange and Interest Income	Foreign Exchange and Interest Expense
Principle Shareholders	Kent Income	Kent Expense	Income	Expense	Hicome	Expense
Yıldız Holding A.Ş.	30.456	(2.233)	98.105	(23.219.548)	59.139.690	(810.108)
Other Companies						
Hero Gıda Sanayi ve Tic.A.Ş.	600	-	446.387	(120.199)	-	-
Hüner Pazarlama San. ve Tic. A.Ş.	144.679	-	95.521	(3.259)	-	-
Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.	13.311	-	237.839	(82.785)	-	-
Önem Gıda San. ve Tic. A.Ş.	610.282	(1.500)	2.260.755	(4.688)	4.189	(165.903)
Northstar Innovation A.Ş.	20.732	-	5.458	(2.382.716)	-	-
İzsal Gayrimenkul Geliştirme A.Ş.	-	(229.526)	-	(91.504)	-	-
Other	212.422	(1.379)	432.204	(1.130.404)	8.508.025	(1.696.539)
	1.032.482	(234.638)	3.576.269	(27.035.103)	67.651.904	(2.672.550)

e) Benefits provided to board members and key management personnel:

	30 September	30 September
	2014	2013
Fees and other short term benefits	7.025.252	13.395.910
	7.025.252	13.395.910

f) There are not any guarantees, commitments and advances given in favor of related parties.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

22. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS

Foreign currency risk management

As of balance sheet date, the foreign currency denominated assets and liabilities of monetary and non-monetary items are as follows:

			30 September	2014		
	TRY Equivalents (Functional				~~~	
1. Trade Receivables	Currency) 65.219.224	24.210.195	3.420.217	42.616	CHF	DKK
2a. Monetary Financial Assets	338.541.104	147.540.886	747.236	32.205	8.726	25.338
2b. Non-Monetary Financial Assets	769.207	337.534	747.230	32.203	6.720	23.336
3. Other	12.461.204	683.956	3.763.655	_	8.497	-
4. CURRENT ASSETS	416.990.739	172.772.571	7.931.108	74.821	17.223	25.338
5. Trade receivables	-	172.772.371	7.531.100	74.021	17,225	23.330
6a. Monetary Financial Assets	27.119	11.900	_	_	_	_
6b. Non-Monetary Financial Assets	_,,,,,	-	-	_	_	_
7. Other	2.939.958	_	1.009.273	5.888	_	_
8. NON-CURRENT ASSETS	2.967.077	11.900	1.009.273	5.888	-	_
9. TOTAL ASSETS	419.957.816	172.784.471	8.940.381	80.709	17.223	25.338
10. Trade Payables	19.725.063	6.090.831	1.885.712	25.499	2.911	750.799
11. Financial Liabilities	831.182.680	182.706.334	143.464.487	-	-	-
12a. Other Monetary Financial Liabilities	84.429	-	29.200	-	-	-
12b. Other Non-Monetary Financial Liabilities	33.529	14.713	-	-	-	-
13. SHORT-TERM LIABILITIES	851.025.701	188.811.878	145.379.399	25.499	2.911	750.799
14. Trade Payables	-	-	-	-	-	-
15. Financial Liabilities	-	-	-	-	-	-
16a. Other Monetary Financial						
Liabilities	-	-	-	-	-	-
16b. Other Non-Monetary Financial Liabilities	-	-	-	-	-	-
17. LONG-TERM LIABILITIES	-	-	-	-	-	-
18. TOTAL LIABILITIES	851.025.701	188.811.878	145.379.399	25.499	2.911	750.799
19. Net foreign currency asset/liability position	(431.067.885)	(16.027.407)	(136.439.018)	55.210	14.312	(725.461)
20. Net foreign currency asset / liability position of monetary items (1+2a+5+6a-10-11-12a-14-15-16a)	(447.204.725)	(17.034.184)	(141.211.946)	49.322	5.815	(725.461)

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

22. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENT (cont'd)

Foreign currency risk management (cont'd)

			31 December 20	13		
	TRY Equivalents (Functional Currency)	USD	EUR	GBP	СНБ	DKK
1. Trade Receivables	153.318.398	58.327.991	9.328.182	<u> </u>	409.170	- DIXIX
2a. Monetary Financial Assets	1.018.500.873	324.964.420	110.617.650	6.289	23.450	8.167
2b. Non-Monetary Financial Assets	610.376	285.984	-	_	_	_
3. Other	2.436.185	757.657	277.050	_	_	14.147
4. CURRENT ASSETS	1.174.865.832	384.336.052	120,222,882	6.289	432.620	22,314
5. Trade receivables	-	-	-	-	-	-
6a. Monetary Financial Assets	25.398	11.900	-	-	-	_
6b. Non-Monetary Financial Assets	-	-	-	-	_	_
7. Other	5.358.025	-	1.814.527	-	8.448	-
8. NON-CURRENT ASSETS	5.383.423	11.900	1.814.527	-	8.448	-
9. TOTAL ASSETS	1.180.249.255	384.347.952	122.037.409	6.289	441.068	22.314
10. Trade Payables	30.731.446	12.063.339	1.652.674	6.543	33.020	_
11. Financial Liabilities	1.245.362.925	367.526.290	156.973.119	-	-	-
12a. Other Monetary Financial Liabilities	522.895	-	171.939	7.530	-	-
12b. Other Non-Monetary Financial Liabilities	7.574.597	3.187.260	261.131	-	1.485	-
13. SHORT-TERM LIABILITIES	1.284.191.863	382.776.889	159.058.863	14.073	34.505	-
14. Trade Payables	-	-	-	-	-	-
15. Financial Liabilities	9.851.176	-	3.354.734	-	-	-
16a. Other Monetary Financial						
Liabilities	-	-	-	-	-	-
16b. Other Non-Monetary Financial						
Liabilities		-	-	-	-	
17. LONG-TERM LIABILITIES	9.851.176	-	3.354.734	-	-	-
18. TOTAL LIABILITIES	1.294.043.039	382.776.889	162.413.597	14.073	34.505	-
19. Net foreign currency asset/liability position	(113.793.784)	1.571.063	(40.376.188)	(7.784)	406.563	22.314
20. Net foreign currency asset/ liability position of monetary items (1+2a+5+6a-10-11-12a-14- 15-16a)	(114.623.773)	3.714.682	(42.206.634)	(7.784)	399.600	8.167

The Group's export and import balances for the nine month period are presented below:

	1 January - 30 September 2014	1 January - 30 September 2013
Total exports Total imports	376.902.950 80.707.907	370.021.148 49.417.235

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

22. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENT (cont'd)

Foreign currency risk sensitivity

The Group is exposed to foreign exchange risk arising primarily from USD and EUR. In the table below, the foreign currency sensitivity of the Company arising from 10% change in US dollar and EUR rates. 10% is the rate used when reporting to senior management of the Company. This rate is the anticipated rate change of the Company's senior management. Sensitivity analysis includes only the monetary items in foreign currency at year end and shows the effect of 10% increase in USD and in EUR foreign currency rates. Negative value implies the effect of 10% increase in USD and in EUR foreign currency rates against TRY on the decrease in the net profit.

	30 Septen	nber 2014	30 Septembe	er 2013
	Income /	Expense	Income / Ex	rpense
	Appreciation of	Depreciation of	Appreciation of	Depreciation of
	foreign currency	foreign currency	foreign currency	foreign currency
	In case of 109	% appreciation of USD ag	gainst TRY	
1 - US Dollar net asset / liability	(3.881.920)	3.881.920	21.325.211	(21.325.211)
2- Part of hedged from US Dollar risk (-)				
3- US Dollar net effect (1+2)	(3.881.920)	3.881.920	21.325.211	(21.325.211)
	In case of 10% a	ppreciation of EUR again	ast TRY	
4 - Euro net asset / liability	(40.830.022)	40.830.022	(27.927.989)	27.927.989
5 - Part of hedged from Euro risk (-)	,		,	
6- Euro net effect (4+5)	(40.830.022)	40.830.022	(27.927.989)	27.927.989
Total (3+6)	(44.711.942)	44.711.942	(6.602.778)	6.602.778

23. FINANCIAL INSTRUMENTS

Fair Value of Financial Instruments

The fair values of financial assets and financial liabilities are determined as follows:

- First level: The fair value of financial assets and financial liabilities are determined with reference to actively traded market prices.
- Second level: Other than market prices specified at first level, the fair value of financial assets and financial liabilities are evaluated with reference to inputs that used to determine directly or indirectly observable price in market.
- Third level: The fair value of financial assets and financial liabilities are evaluated with reference to inputs that used to determine fair value but not relying on observable data in the market.

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

 $(Amounts\ expressed\ in\ Turkish\ Lira\ (TRY)\ unless\ otherwise\ stated.)$

23. FINANCIAL INSTRUMENTS (cont'd)

Fair Value of Financial Instruments (cont'd)

The classification of the Company's financial assets and liabilities at fair value is as follows:

		Fair Value Level of Financial Assets as Reporting Date			
Financial Assets	30 September 2014	Level 1 TRY	Level 2 TRY		
Financial assets for which fair value differences reflected through profit and loss					
- Held for trading- Shares	770.107	770.107	-	-	
Financial assets for which fair value differences reflected through profit and loss	-	-	-	_	
- Shares	467.145.251	28.552.357	-	438.592.894	
Total	467.915.358	29.322.464	-	438.592.894	
		Fair Value Leve Re	el of Financial A porting Date	Assets as of	
Financial Assets	December 2013	Level 1 TRY	Level 2 TRY	Level 3 TRY	
Financial assets for which fair value differences reflected through profit and loss					
- Held for trading	611.476	611.476	-	-	
- Shares	-	-	-	-	
Financial assets for which fair value differences reflected through profit and loss					
- Shares	464.418.845	25.825.951	-	438.592.894	
Total	465.030.321	26.437.427	-	438.592.894	

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

23. FINANCIAL INSTRUMENTS (cont'd)

Fair Value of Financial Instruments (cont'd)

Reconciliation of level 3 financial assets or liabilities as of beginning and ending period is as follows;

	1 January - 30 September 2014	1 January- 30 September 2013
Opening Balance Total Gain/Loss	438.592.894	299.824.640
- Classified under other comprehensive income	-	-
Closing Balance	438.592.894	299.824.640

24. EVENTS AFTER THE BALANCE SHEET DATE

None.

25. SALES OF SUBSIDIARIES

a) <u>İstanbul Gıda Dış Ticaret A.Ş. Sales</u>: The Company has sold out its subsidiary with 91,41% İstanbul Gıda Dış.Tic.A.Ş. for an amount of TRY 28.551.007 to its parent Yıldız Holding A.Ş. as of 6 May 2014. Due to the sales has occurred to parent Yıldız Holding A.Ş, subsidiary's sale loss has evaluated as "Transaction between under common control" and accounted under Shareholder's Equity.

Disposal net asset due to transaction and the effect of the transaction in equity is as follows;

Assets without Scope of Consolidation	Asset/(Liability)
Current Assets	
Cash and Cash Equivalents	365.447.910
Trade Receivables	96.515.222
Other Receivables	21.936.350
Other Current Assets	4.798.416
Non-Current Assets	
Tangible-Intangible Assets (Net)	247.514
Deferred Tax Assets	489.728
Other Non-Current Assets	3
Current Liabilities	
Financial Liabilities	(293.472.058)
Trade Payables	(43.211.397)
Other Payables	(2.347.901)
Other Current Liabilities	(14.112.566)
Non-Current Liabilities	
Other Non-Current Liabilities	(109.824.529)
Net Asset without Scope of Consolidation	26.466.692
Net Cash Generated from Subsidiaries Sales	28.551.007
Net Equity Impact from Sales of Subsidiaries	2.084.315

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

25. SALES OF SUBSIDIARIES (cont'd)

b) <u>Birleşik Dış Ticaret A.Ş. Sales</u>: The Company has sold out its subsidiary with 79,17% Birleşik Dış Tic.A.Ş. for an amount of TRY 3.200.000 to its parent Yıldız Holding A.Ş. as of 6 May 2014. Due to the sales has occurred to parent Yıldız Holding A.Ş, subsidiary's sale gain has evaluated as "Transaction between under common control" and accounted under Shareholder's Equity.

Disposal net asset due to transaction and the effect of the transaction in equity is as follows;

Assets without Scope of Consolidation	Asset/(Liability)
Current Assets	
Cash and Cash Equivalents	3.946.034
Trade Receivables	18.653.426
Other Receivables	50.610.795
Other Current Assets	178.961
Non-Current Assets	
Tangible-Intangible Assets (Net)	1.055.898
Deferred Tax Assets	18.106
Other Non-Current Assets	42.274
Current Liabilities	
Financial Liabilities	(50.280.566)
Trade Payables	(19.478.341)
Other Payables	-
Other Current Liabilities	(1.826.253)
Non-Current Liabilities	
Other Non-Current Liabilities	(742.284)
Net Asset without Scope of Consolidation	2.178.050
Net Cash Generated from Subsidiaries Sales	3.200.000
Net Equity Impact from Sales of Subsidiaries	1.021.950

ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 SEPTEMBER 2014

(Amounts expressed in Turkish Lira (TRY) unless otherwise stated.)

25. SALES OF SUBSIDIARIES (cont'd)

c) Rekor Gıda Pazarlama A.Ş. Sales: One of Ülker Bisküvi San.A.Ş's subsidiary Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş. has sold out it's 100% subsidiary Rekor Gıda Pazarlama A.Ş (Ülker Bisküvi has 43,92% share indirectly) for an amount of TRY 4.000.000 to its parent Yıldız Holding A.Ş. as of 6 May 2014. Due to the sales has occurred to parent Yıldız Holding A.Ş, subsidiary's sale loss has evaluated as "Transaction between under common control" and accounted under Shareholder's Equity.

Disposal net asset due to transaction and the effect of the transaction in equity is as follows;

Assets without Scope of Consolidation	Asset/(Liability)
Current Assets	
Cash and Cash Equivalents	8.743.686
Trade Receivables	50.508.869
Other Receivables	211.034
Other Current Assets	2.994.698
Non-Current Assets	
Tangible-Intangible Assets (Net)	239.940
Deferred Tax Assets	1.806.245
Other Non-Current Assets	-
Current Liabilities	
Financial Liabilities	-
Trade Payables	(55.573.735)
Other Payables	-
Other Current Liabilities	(4.946.117)
Non-Current Liabilities	
Other Non-Current Liabilities	(202.164)
Net Asset without Scope of Consolidation	3.782.456
Net Cash Generated from Subsidiaries Sales	4.000.000
Net Equity Impact from Sales of Subsidiaries	217.544

Breakdown of non-controlling interest and equity holders of the parent related to the subsidiary disposals are as follows;

	Non-	
	Controlling	Equity Holders of
	Interest	the Parent
İstanbul Gıda Dış Ticaret A.Ş.	179.076	1.905.239
Birleşik Dış Ticaret A.Ş.	212.872	809.078
Rekor Gıda Pazarlama A.Ş.	122.007	95.537
Total	513.955	2.809.854